Comparative Pharmacology
Head-to-head clinical analysis: FLAC versus NASONEX 24HR ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAC versus NASONEX 24HR ALLERGY.
FLAC vs NASONEX 24HR ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
Glucocorticoid receptor agonist; inhibits inflammatory mediators including cytokines, chemokines, and adhesion molecules; reduces nasal inflammation.
Adults: 40 mg orally twice daily.
2 sprays (50 mcg/spray) per nostril once daily; total dose 200 mcg/day.
None Documented
None Documented
2-4 hours; prolonged in renal impairment (up to 12 hours)
The terminal elimination half-life of mometasone furoate is approximately 5.8 hours. This short half-life supports once-daily dosing for intranasal use, but systemic accumulation is minimal with topical administration.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Mometasone furoate is predominantly eliminated via biliary/fecal excretion. After intravenous administration, approximately 74% of the dose is recovered in feces and about 8% in urine. The drug undergoes extensive hepatic metabolism, and metabolites are excreted primarily in bile.
Category C
Category C
Corticosteroid
Corticosteroid, Intranasal